Stock market analysts have maintained ‘buy’ rating on Fresenius Kabi Oncology Ltd with an intraday target of Rs 105.

According to them, interested traders can purchase the stock around Rs 103 with a strict stop loss of Rs 101.

If the bourses remain on the positive track, then the stock price will hit a target above Rs 107.

Shares of the company, on Thursday (Dec 03), closed at Rs 197.45 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 104 and a low of Rs 32.50 on BSE.

Formerly known as Dabur Pharma Ltd, the major activities of Fresenius Kabi Oncology Ltd include production and sale of oral and injectable dosage forms and active pharmaceutical components and intermediates.

The company works in two sections including formulation and bulk drug.

Fresenius Kabi works in the area of cancer study and antitumor products. It sells products in the antidiabetic, antibacterial, cardiovascular & digestive sections.

The company sells its products in Costa Rica, Thailand, Nepal, Zimbabwe, Bangladesh, Venezuela, Ukraine, Sri Lanka, Kenya, India, Nigeria, Ghana, Philippines, Malaysia, Colombia, Jamaica, Barbados, Brazil, Vietnam, Myanmar, Mexico, Jordan, Cyprus, Russia, Ukraine, Hungary, Belarus, Georgia and Peru.

Its plants are situated in Himachal Pradesh and West Bengal.